Abstract
Summary
Nuclear medicine therapy uses radiopharmaceuticals targeting specific tumors, such as thyroid tumors, lymphomas, or bone metastases, to deliver radiation to neoplastic lesions as part of a therapeutic strategy to cure, alleviate, or control the disease.
The global market for Radiopharmaceutical Theranostics was estimated to be worth US$ 745.6 million in 2023 and is forecast to a readjusted size of US$ 986.5 million by 2030 with a CAGR of 4.1% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical Theranostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radiopharmaceutical Theranostics by region & country, by Type, and by Application.
The Radiopharmaceutical Theranostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical Theranostics.
Market Segmentation
By Company
Nihon Medi-Physics
ITM Isotopen Technologien München AG
Advanced Accelerator Applications
Telix Pharmaceuticals
GE Healthcare
Theragnostics Ltd.
NuView Life Sciences
Jubilant Pharma Limited
Lantheus Holdings, Inc.
Curium Pharma
Bayer AG
Clarity Pharmaceuticals
Segment by Type:
Oncology
Cardiology
Others
Segment by Application
Hospitals
Academic & Research Institutes
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Radiopharmaceutical Theranostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Radiopharmaceutical Theranostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Radiopharmaceutical Theranostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Radiopharmaceutical Theranostics was estimated to be worth US$ 745.6 million in 2023 and is forecast to a readjusted size of US$ 986.5 million by 2030 with a CAGR of 4.1% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceutical Theranostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radiopharmaceutical Theranostics by region & country, by Type, and by Application.
The Radiopharmaceutical Theranostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceutical Theranostics.
Market Segmentation
By Company
Nihon Medi-Physics
ITM Isotopen Technologien München AG
Advanced Accelerator Applications
Telix Pharmaceuticals
GE Healthcare
Theragnostics Ltd.
NuView Life Sciences
Jubilant Pharma Limited
Lantheus Holdings, Inc.
Curium Pharma
Bayer AG
Clarity Pharmaceuticals
Segment by Type:
Oncology
Cardiology
Others
Segment by Application
Hospitals
Academic & Research Institutes
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Radiopharmaceutical Theranostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Radiopharmaceutical Theranostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Radiopharmaceutical Theranostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Radiopharmaceutical Theranostics Product Introduction
1.2 Global Radiopharmaceutical Theranostics Market Size Forecast
1.3 Radiopharmaceutical Theranostics Market Trends & Drivers
1.3.1 Radiopharmaceutical Theranostics Industry Trends
1.3.2 Radiopharmaceutical Theranostics Market Drivers & Opportunity
1.3.3 Radiopharmaceutical Theranostics Market Challenges
1.3.4 Radiopharmaceutical Theranostics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Radiopharmaceutical Theranostics Players Revenue Ranking (2023)
2.2 Global Radiopharmaceutical Theranostics Revenue by Company (2019-2024)
2.3 Key Companies Radiopharmaceutical Theranostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Radiopharmaceutical Theranostics Product Offered
2.5 Key Companies Time to Begin Mass Production of Radiopharmaceutical Theranostics
2.6 Radiopharmaceutical Theranostics Market Competitive Analysis
2.6.1 Radiopharmaceutical Theranostics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Radiopharmaceutical Theranostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceutical Theranostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oncology
3.1.2 Cardiology
3.1.3 Others
3.2 Global Radiopharmaceutical Theranostics Sales Value by Type
3.2.1 Global Radiopharmaceutical Theranostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Radiopharmaceutical Theranostics Sales Value, by Type (2019-2030)
3.2.3 Global Radiopharmaceutical Theranostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Academic & Research Institutes
4.1.3 Others
4.2 Global Radiopharmaceutical Theranostics Sales Value by Application
4.2.1 Global Radiopharmaceutical Theranostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Radiopharmaceutical Theranostics Sales Value, by Application (2019-2030)
4.2.3 Global Radiopharmaceutical Theranostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Radiopharmaceutical Theranostics Sales Value by Region
5.1.1 Global Radiopharmaceutical Theranostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Radiopharmaceutical Theranostics Sales Value by Region (2019-2024)
5.1.3 Global Radiopharmaceutical Theranostics Sales Value by Region (2025-2030)
5.1.4 Global Radiopharmaceutical Theranostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Radiopharmaceutical Theranostics Sales Value, 2019-2030
5.2.2 North America Radiopharmaceutical Theranostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Radiopharmaceutical Theranostics Sales Value, 2019-2030
5.3.2 Europe Radiopharmaceutical Theranostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Radiopharmaceutical Theranostics Sales Value, 2019-2030
5.4.2 Asia Pacific Radiopharmaceutical Theranostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Radiopharmaceutical Theranostics Sales Value, 2019-2030
5.5.2 South America Radiopharmaceutical Theranostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Radiopharmaceutical Theranostics Sales Value, 2019-2030
5.6.2 Middle East & Africa Radiopharmaceutical Theranostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Radiopharmaceutical Theranostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Radiopharmaceutical Theranostics Sales Value
6.3 United States
6.3.1 United States Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.3.2 United States Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.4.2 Europe Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.5.2 China Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.6.2 Japan Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.7.2 South Korea Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.8.2 Southeast Asia Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Radiopharmaceutical Theranostics Sales Value, 2019-2030
6.9.2 India Radiopharmaceutical Theranostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Radiopharmaceutical Theranostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Nihon Medi-Physics
7.1.1 Nihon Medi-Physics Profile
7.1.2 Nihon Medi-Physics Main Business
7.1.3 Nihon Medi-Physics Radiopharmaceutical Theranostics Products, Services and Solutions
7.1.4 Nihon Medi-Physics Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.1.5 Nihon Medi-Physics Recent Developments
7.2 ITM Isotopen Technologien München AG
7.2.1 ITM Isotopen Technologien München AG Profile
7.2.2 ITM Isotopen Technologien München AG Main Business
7.2.3 ITM Isotopen Technologien München AG Radiopharmaceutical Theranostics Products, Services and Solutions
7.2.4 ITM Isotopen Technologien München AG Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.2.5 ITM Isotopen Technologien München AG Recent Developments
7.3 Advanced Accelerator Applications
7.3.1 Advanced Accelerator Applications Profile
7.3.2 Advanced Accelerator Applications Main Business
7.3.3 Advanced Accelerator Applications Radiopharmaceutical Theranostics Products, Services and Solutions
7.3.4 Advanced Accelerator Applications Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.3.5 Telix Pharmaceuticals Recent Developments
7.4 Telix Pharmaceuticals
7.4.1 Telix Pharmaceuticals Profile
7.4.2 Telix Pharmaceuticals Main Business
7.4.3 Telix Pharmaceuticals Radiopharmaceutical Theranostics Products, Services and Solutions
7.4.4 Telix Pharmaceuticals Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.4.5 Telix Pharmaceuticals Recent Developments
7.5 GE Healthcare
7.5.1 GE Healthcare Profile
7.5.2 GE Healthcare Main Business
7.5.3 GE Healthcare Radiopharmaceutical Theranostics Products, Services and Solutions
7.5.4 GE Healthcare Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.5.5 GE Healthcare Recent Developments
7.6 Theragnostics Ltd.
7.6.1 Theragnostics Ltd. Profile
7.6.2 Theragnostics Ltd. Main Business
7.6.3 Theragnostics Ltd. Radiopharmaceutical Theranostics Products, Services and Solutions
7.6.4 Theragnostics Ltd. Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.6.5 Theragnostics Ltd. Recent Developments
7.7 NuView Life Sciences
7.7.1 NuView Life Sciences Profile
7.7.2 NuView Life Sciences Main Business
7.7.3 NuView Life Sciences Radiopharmaceutical Theranostics Products, Services and Solutions
7.7.4 NuView Life Sciences Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.7.5 NuView Life Sciences Recent Developments
7.8 Jubilant Pharma Limited
7.8.1 Jubilant Pharma Limited Profile
7.8.2 Jubilant Pharma Limited Main Business
7.8.3 Jubilant Pharma Limited Radiopharmaceutical Theranostics Products, Services and Solutions
7.8.4 Jubilant Pharma Limited Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.8.5 Jubilant Pharma Limited Recent Developments
7.9 Lantheus Holdings, Inc.
7.9.1 Lantheus Holdings, Inc. Profile
7.9.2 Lantheus Holdings, Inc. Main Business
7.9.3 Lantheus Holdings, Inc. Radiopharmaceutical Theranostics Products, Services and Solutions
7.9.4 Lantheus Holdings, Inc. Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.9.5 Lantheus Holdings, Inc. Recent Developments
7.10 Curium Pharma
7.10.1 Curium Pharma Profile
7.10.2 Curium Pharma Main Business
7.10.3 Curium Pharma Radiopharmaceutical Theranostics Products, Services and Solutions
7.10.4 Curium Pharma Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.10.5 Curium Pharma Recent Developments
7.11 Bayer AG
7.11.1 Bayer AG Profile
7.11.2 Bayer AG Main Business
7.11.3 Bayer AG Radiopharmaceutical Theranostics Products, Services and Solutions
7.11.4 Bayer AG Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.11.5 Bayer AG Recent Developments
7.12 Clarity Pharmaceuticals
7.12.1 Clarity Pharmaceuticals Profile
7.12.2 Clarity Pharmaceuticals Main Business
7.12.3 Clarity Pharmaceuticals Radiopharmaceutical Theranostics Products, Services and Solutions
7.12.4 Clarity Pharmaceuticals Radiopharmaceutical Theranostics Revenue (US$ Million) & (2019-2024)
7.12.5 Clarity Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Radiopharmaceutical Theranostics Industrial Chain
8.2 Radiopharmaceutical Theranostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Radiopharmaceutical Theranostics Sales Model
8.5.2 Sales Channel
8.5.3 Radiopharmaceutical Theranostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer